- Home
- CYN vs IGC Comparison
CYN vs IGC Comparison
Compare CYN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- IGC
- Stock Information
- Founded
- CYN 2013
- IGC 2005
- Country
- CYN United States
- IGC United States
- Employees
- CYN N/A
- IGC N/A
- Industry
- CYN EDP Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CYN Technology
- IGC Health Care
- Exchange
- CYN Nasdaq
- IGC Nasdaq
- Market Cap
- CYN 42.0M
- IGC 39.8M
- IPO Year
- CYN 2021
- IGC N/A
- Fundamental
- Price
- CYN $5.99
- IGC $0.42
- Analyst Decision
- CYN
- IGC Strong Buy
- Analyst Count
- CYN 0
- IGC 2
- Target Price
- CYN N/A
- IGC $4.00
- AVG Volume (30 Days)
- CYN 296.4K
- IGC 695.2K
- Earning Date
- CYN 11-05-2025
- IGC 11-11-2025
- Dividend Yield
- CYN N/A
- IGC N/A
- EPS Growth
- CYN N/A
- IGC N/A
- EPS
- CYN N/A
- IGC N/A
- Revenue
- CYN $434,837.00
- IGC $1,327,000.00
- Revenue This Year
- CYN $31.96
- IGC $15.26
- Revenue Next Year
- CYN $1,459.25
- IGC $3.41
- P/E Ratio
- CYN N/A
- IGC N/A
- Revenue Growth
- CYN 445.29
- IGC 24.95
- 52 Week Low
- CYN $3.62
- IGC $0.25
- 52 Week High
- CYN $1,312.50
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CYN 51.75
- IGC 52.73
- Support Level
- CYN $5.95
- IGC $0.39
- Resistance Level
- CYN $6.82
- IGC $0.43
- Average True Range (ATR)
- CYN 0.41
- IGC 0.02
- MACD
- CYN 0.09
- IGC -0.00
- Stochastic Oscillator
- CYN 42.86
- IGC 44.42
About CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.